摘要
目的:分析武汉地区24家医院抗病毒药的利用情况及趋势。方法:采用回顾性方法,对武汉地区24家医院2007-2010年抗病毒药的销售金额、用药频度(DDDs)和日均费用(DDC)等进行统计、分析。结果:4年来该地区医院抗病毒药总销售金额呈逐年上升趋势,居前5位的药物均为核苷类抗病毒药,约占总销售额的90%;阿德福韦酯、拉米夫定的DDDs较高,一直居前2位;金刚烷胺的DDC最低(约0.13元/日),其次是三氮唑核苷(低于5元/日);销售金额排序列前20位的制药企业中,前4位全部是进口企业或合资企业。结论:抗病毒药品种相对较少,主要为核苷类抗病毒药,国内企业生产的抗病毒药所占份额较小,因此应加强抗病毒药的研发,增强国有抗病毒药的国际竞争力。
OBJECTIVE： To evaluate the status quo and developmental trend of the utilization of antiviral drugs in 24 hospitals of Wuhan area from 2007 to 2010. METHODS： Using retrospective method, utilization of antiviral drugs was analyzed statistically in respect of consumption sum, DDDs and DDC, etc. RESULTS： Over the 4 years, the total consumption sum of antiviral drugs in Wuhan area increased year by year. The top 5 drugs were all nucleoside antiviral, accounting for about 90% of total consumptions. The DDDs of adefovir dipivoxil and lamivudine were higher than that of any others. In addition, the DDC of amantadine was the lowest about （about 0.13 yuan/day）, followed by ribavirin（ less than 5 yuardday）. Among the top 20 pharmaceutical companies in the list of consumption sum, the top 4 were all import enterprises or joint ventures. CONCLUSION： There are a few species of antiviral drugs relatively, mainly including nucleoside antiviral drugs. Moreover, the amount of antiviral drugs produced by domestic companies shares very small proportion. Therefore, the development of antiviral drugs should be strengthened and the international competitiveness of state-owned antiviral drugs should be enhanced.
出处
《中国药房》
CAS
CSCD
2012年第6期498-501,共4页
China Pharmacy
